Processa Pharmaceuticals (PCSA) CFO adds 2,292 shares in open-market buy

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of Common Stock. On May 29, 2026, he bought 2,292 shares at $2.57 per share, bringing his directly held position to 10,758 shares after the transaction.

Insider Trade Summary

Net Buyer: 2,292 shares ($5,890)

Net Buy 1 txn

Insider SKIBSTED RUSSELL

Role Chief Financial Officer

Bought 2,292 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,292	$2.57	$6K

Holdings After Transaction: Common Stock — 10,758 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 2,292 shares Purchase price: $2.57 per share Shares held after: 10,758 shares +1 more

4 metrics

Shares purchased 2,292 shares Open-market purchase on May 29, 2026

Purchase price $2.57 per share Common Stock transaction

Shares held after 10,758 shares Direct ownership following transaction

Net buy shares 2,292 shares Net change in position in this filing

Key Terms

open-market purchase, Common Stock, Form 4, direct ownership

4 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

direct ownership financial

"ownership_type: "direct" and ownership_code: "D""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SKIBSTED RUSSELL

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		P		2,292	A	$2.57	10,758	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA’s CFO report on this Form 4?

Processa Pharmaceuticals’ CFO Russell Skibsted reported an open-market purchase of Common Stock. He acquired 2,292 shares on May 29, 2026 at $2.57 per share, increasing his directly held stake to 10,758 shares following the transaction.

How many Processa Pharmaceuticals (PCSA) shares did the CFO buy?

The CFO bought 2,292 shares of Processa Pharmaceuticals Common Stock. This open-market purchase on May 29, 2026 was reported as a direct ownership transaction and raised his total directly held position to 10,758 shares after the trade.

At what price did the PCSA CFO purchase his shares in this filing?

Russell Skibsted purchased his PCSA Common Stock at $2.57 per share. The Form 4 shows an open-market transaction for 2,292 shares on May 29, 2026, resulting in total direct holdings of 10,758 shares after the purchase.

What are the CFO’s total PCSA share holdings after this reported trade?

After this transaction, the CFO directly holds 10,758 shares of Processa Pharmaceuticals. The Form 4 indicates this total reflects his position following the open-market purchase of 2,292 Common Stock shares executed on May 29, 2026 at $2.57 per share.

Is the PCSA CFO’s transaction a buy or sell according to the Form 4?

The Form 4 classifies the CFO’s activity as a buy transaction. It records an open-market purchase of 2,292 Common Stock shares on May 29, 2026 at $2.57 each, increasing his direct ownership to 10,758 shares after the trade.